Form 4: Spruce Biosciences Reprices Executive Stock Options

Spruce Biosciences has repriced stock options for its President and CFO, Samir M. Gharib, and other eligible employees and directors, lowering the exercise price to $104.13 per share.

Summary

• Spruce Biosciences, Inc. implemented a one-time stock option repricing effective December 11, 2025.
• The repricing applies to options with original exercise prices of $106.09 per share or greater, held by employees and directors who maintained continuous service with the company as of the repricing date.
• The new exercise price for these repriced options has been set at $104.13 per share, which corresponds to the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the repricing date.
• Samir M. Gharib, President and CFO, had multiple tranches of his stock options repriced, including 1,579 shares (from $123 to $104.13), 953 shares (from $230.25 to $104.13), 733 shares (from $1,506 to $104.13), 1,933 shares (from $186 to $104.13), and 933 shares (from $344.25 to $104.13).
• A retention period of one year is in effect, during which optionholders exercising repriced options will be required to pay the original, higher exercise price per share.
• No other terms of the repriced options, such as vesting schedules, expiration dates, or the number of shares underlying the options, were altered.

Sentiment

Score: 3

Explanation: The repricing of stock options, while beneficial for employee retention, is a strong indicator of significant past stock price underperformance. It suggests that the company's market valuation has declined substantially, which is generally a negative signal for investors, despite the positive intent for employee morale.

Positives

• The repricing makes previously 'underwater' stock options exercisable and valuable again for eligible employees and directors, including President and CFO Samir M. Gharib.
• This action can help retain key talent by restoring the incentive value of equity compensation, which is crucial for long-term company stability and growth.
• The new exercise price of $104.13 per share is significantly lower than the original exercise prices, which ranged from $123 to $1,506 per share, providing a renewed potential for future gains for option holders.

Negatives

• The necessity of a stock option repricing indicates a significant decline in the company's stock price, as the original exercise prices were substantially higher than the current market price.
• The repricing could be perceived negatively by existing shareholders who have seen their equity value diminish, as it effectively makes more options 'in-the-money' at a lower price, potentially leading to future dilution.
• The one-year retention period, requiring payment of the original exercise price if exercised early, adds a layer of complexity and potential disincentive for immediate exercise.

Risks

• The repricing itself is a symptom of a significant decline in the company's stock price, indicating underlying business challenges or negative market perception.
• Potential for negative shareholder sentiment due to the perceived unfairness of repricing options for management and employees while existing shareholders bear the full brunt of the stock price decline.
• The retention period, while intended to encourage long-term service, could still lead to a wave of exercises after the period ends, potentially increasing selling pressure on the stock.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the terms of the repriced options and their vesting schedules.

Management Comments

• The filing includes the signature of Samir Gharib, indicating his acknowledgment of the reported transactions, but no direct quotes or paraphrased statements are provided.

Industry Context

Stock option repricing is a common practice in industries, particularly biotechnology or high-growth sectors, where company stock prices have experienced significant declines, rendering existing options 'underwater' and ineffective as an incentive. This action by Spruce Biosciences suggests that its stock has underperformed, similar to other companies in volatile sectors facing market headwinds or specific clinical/commercial setbacks. The goal is typically to re-motivate employees and retain talent by restoring the value of their equity compensation.

Comparison to Industry Standards

• Stock option repricing is a recognized, albeit often controversial, mechanism used by companies to address underwater options. While specific comparable companies or projects are not mentioned in the filing, such repricings are typically seen in companies whose stock has fallen significantly below previous grant prices.
• For example, many biotech companies that went public during periods of high valuations have subsequently seen their stock prices decline, leading to similar repricing events to retain talent.
• The one-year retention period requiring payment of the original exercise price if exercised early is a common protective measure to mitigate immediate dilution and encourage continued service, aligning with some best practices for such programs.

Related Party Transactions

• The filing details stock option transactions for an officer (Samir M. Gharib), which are considered related party transactions in the context of executive compensation.

Stakeholder Impact

• Shareholders: Existing shareholders may experience dilution and negative sentiment due to the repricing, as it effectively makes more options 'in-the-money' at a lower valuation, potentially increasing the number of shares outstanding upon exercise.
• Employees/Management: Eligible employees and directors, including the President and CFO, benefit significantly as their previously underwater stock options regain incentive value, potentially improving morale and retention.

Next Steps

• Optionholders will continue to vest in their repriced options according to their original schedules.
• Optionholders will be subject to a one-year retention period where exercising repriced options would require paying the original, higher exercise price.

Key Dates

Recommendation

The stock option repricing indicates significant past stock price underperformance, which is a negative signal. However, the repricing itself is a strategic move to retain key talent, which is crucial for the company's long-term prospects. Without further information on the company's operational performance or future outlook, a 'hold' recommendation is appropriate. Investors should monitor future financial reports and strategic announcements to assess the effectiveness of this retention strategy and the company's ability to reverse its stock price decline.

Keywords

Spruce Biosciences, SPRB, stock option repricing, executive compensation, Form 4, Samir M. Gharib, equity incentive plan, Nasdaq Capital Market, volume-weighted average price